GH Research PLC (GHRS)vsRoyalty Pharma Plc (RPRX)
GHRS
GH Research PLC
$26.17
-7.83%
HEALTHCARE · Cap: $1.95B
RPRX
Royalty Pharma Plc
$56.92
-1.47%
HEALTHCARE · Cap: $32.78B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
GHRS
Avoid23
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GHRS.
Margin of Safety
-64.1%
Fair Value
$34.68
Current Price
$56.92
$22.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GHRS
The strongest argument for GHRS centers on Debt/Equity, Altman Z-Score.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : GHRS
The primary concerns for GHRS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
GHRS profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
GHRS carries more volatility with a beta of 1.31 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 23/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GH Research PLC
HEALTHCARE · BIOTECHNOLOGY · USA
GH Research PLC is a clinical-stage biopharmaceutical company specializing in the development of psilocybin-based therapies targeted at psychiatric and neurodegenerative disorders. With a strong pipeline designed to meet significant unmet needs in mental health treatment, the company is led by an experienced team dedicated to advancing innovative therapeutic solutions. By leveraging its unique scientific approach, GH Research aims to transform treatment paradigms and improve patient outcomes, positioning itself as a potential leader in the burgeoning mental health therapeutics market.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?